In the univariate analysis, high EZH2 protein expression was a strong independent predictor of poor 5-year PFS in patients with gliomas, with a higher risk of recurrence (hazard ratio of 5.841 with 95% confidence interval 2.231–15.292, p < 0.0001). This evidence concerns the gene EZH2 and central nervous system cancer.